Literature DB >> 21969034

Characterization of ligand type of estrogen receptor by MD simulation and mm-PBSA free energy analysis.

Jing-Yuan Liu1, Sean D Mooney.   

Abstract

Estrogen receptor is a transcription regulator and can bind structurally distinct ligands with full agonistic, SERMs, or full antagonistic properties. Crystal structures of the ER ligand binding domain (LBD)-complexed with full agonists or SERMs show that these ligands induce two different orientations of Helix12 in LBD and generate two different conformations, agonist conformation (A conformation) and AF2 antagonist conformation (B conformation). To understand how ER ligands interact with LBD structurally and energetically, we docked 3 full agonists, 9 SERMs and 2 full antagonists in both the A and B conformation of ERα LBD and performed a 4-step molecular dynamics (MD) simulation on all 28 complexes followed by mm-PBSA binding free energy calculation. We found that all full agonists prefer the A conformation while all SERMs prefer the B conformation. Analysis of the mm-PBSA energies revealed that calculated total binding free energies (delta PBTOT) and the difference of VDW between complex and the sum of receptor of ligands and ligand (delta VDW) have the order of full agonists>SERMs>full antagonists. However, the PB surface term has the order of full antagonists>SERMs>full agonists. We also found that the sum of the RMSD of mainchain atoms of Helix12 and all atoms of ligands in the A conformation is significantly lower for full agonists than that of the other ligands. Together, we conclude that the three types of ER ligands interact with the A and B conformations of ERα LBD differently and same type of ligands interact similarly. These findings will be useful in understanding the mechanism of ER antagonism and can be used in ligand type prediction.

Entities:  

Year:  2011        PMID: 21969034      PMCID: PMC3180098     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  18 in total

Review 1.  Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions.

Authors:  David M Lonard; Carolyn L Smith
Journal:  Steroids       Date:  2002-01       Impact factor: 2.668

Review 2.  Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.

Authors:  S L Silfen; A V Ciaccia; H U Bryant
Journal:  Climacteric       Date:  1999-12       Impact factor: 3.005

Review 3.  Selective estrogen receptor modulators: tissue actions and potential for CNS protection.

Authors:  M T Littleton-Kearney; N L Ostrowski; D A Cox; M I Rossberg; P D Hurn
Journal:  CNS Drug Rev       Date:  2002

4.  Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.

Authors:  Johanne Renaud; Serge François Bischoff; Thomas Buhl; Philipp Floersheim; Brigitte Fournier; Christine Halleux; Joerg Kallen; Hansjoerg Keller; Jean-Marc Schlaeppi; Wilhelm Stark
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

Review 5.  Selective estrogen receptor modulators: structure, function, and clinical use.

Authors:  C K Osborne; H Zhao; S A Fuqua
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

Review 6.  Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.

Authors:  Tatjana E Vogelvang; Marius J van der Mooren; Velja Mijatovic
Journal:  Treat Endocrinol       Date:  2004

Review 7.  Estrogen receptor alpha in human breast cancer: occurrence and significance.

Authors:  S Ali; R C Coombes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

8.  Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta.

Authors:  J Sun; M J Meyers; B E Fink; R Rajendran; J A Katzenellenbogen; B S Katzenellenbogen
Journal:  Endocrinology       Date:  1999-02       Impact factor: 4.736

Review 9.  How computational methods try to disclose the estrogen receptor secrecy--modeling the flexibility.

Authors:  Francesca Spyrakis; Pietro Cozzini
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

View more
  2 in total

1.  Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer.

Authors:  Amneh Shtaiwi; Rohana Adnan; Melati Khairuddean; Shafi Ullah Khan
Journal:  RSC Adv       Date:  2019-11-01       Impact factor: 4.036

2.  The effect of protein mutations on drug binding suggests ensuing personalised drug selection.

Authors:  Shunzhou Wan; Deepak Kumar; Valentin Ilyin; Ussama Al Homsi; Gulab Sher; Alexander Knuth; Peter V Coveney
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.